Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature by Yan, Dan-Fang et al.
CASE REPORT Open Access
Hemorrhage of brain metastasis from non-small
cell lung cancer post gefitinib therapy:
two case reports and review of the literature
Dan-Fang Yan
1, Sen-Xiang Yan
1*, Jing-Song Yang
1, Yi-Xiang J Wang
2, Xiao-Li Sun
1, Xin-Biao Liao
1, Jun-Qing Liu
1
Abstract
Background: Gefitinib is one of the small molecule inhibitors of epidermal growth factor receptor tyrosine kinase
(EGFR TKIs). Clinical trials have demonstrated it is effective for treatment of a subset of patients with advanced
non-small cell lung cancer (NSCLC). Gefitinib has been generally considered to be a relatively safe agent. Besides a
small proportion of fatal interstitial pneumonia, the common adverse drug reactions of gefitinib include diarrhea
and skin rash, which are generally mild and reversible. Herein, we report the first two cases of brain metastasis
hemorrhage that might be involved with the use of gefitinib.
Case presentation: Two patients with brain metastasis from NSCLC developed brain hemorrhage after gefitinib
therapy. The hemorrhage in one case occurred one month after gefitinib combined with whole brain radiation
therapy (WBRT), and in the another case hemorrhage developed slowly within brain metastases eight months post
gefitinib monotherapy for diffuse pulmonary metastasis from a lung cancer undergone surgical removal previously.
Conclusion: We speculate brain hemorrhage could be one of the adverse drug reactions of gefitinib treatment for
NSCLC and suggest clinicians be aware of this possible rare entity. More data are needed to confirm our findings,
especially when gefitinib is used in the settings of brain metastases from NSCLC or other origins.
Background
Gefitinib is one of the inhibitors of epidermal growth
factor receptor tyrosine kinase (EGFR TKIs), designed to
offer targeted therapies for a variety of solid tumors
including the lung cancer [1]. Clinical trials have
demonstrated that gefitinib is effective or non-inferior
to chemotherapy in the treatment of a subset of patients
with advanced non-small cell lung cancer (NSCLC)
[2-4]. Gefitinib has also been regarded as a relatively
safe agent, with the most common adverse drug reac-
tions being diarrhea and skin rash, which are generally
mild in nature and reversible [5,6]. Here we describe
two cases of brain metastasis from NSCLC who devel-
oped brain hemorrhage post gefitinib therapy. To our
knowledge, these are the first reported cases of brain
hemorrhage that might be involved in the use of gefiti-
nib. Recently, a few hemorrhagic events in other parts
o ft h eb o d yh a v ea l s ob e e nr e p o r t e da f t e rg e f i t i n i b
administration [7-9]. Thus, we speculate brain hemor-
rhage could be one possible adverse drug reaction of
gefitinib treatment for NSCLC.
Case presentation
Case one
A 52-year-old male, who was an ex-smoker with a
smoking history of ten years, was found a solitary pul-
monary nodule (SPN) in the upper lobe of right lung by
CT scans 6 years ago. He refused surgery or any inva-
sive procedures to the nodule. Chest CT scan was per-
formed every six months for follow-up. In May 2009 CT
demonstrated the SPN increased in size with multiple
lung and ribs metastasis (Fig. 1A). Brain MRI showed
multiple metastatic lesions with the largest one in the
left occipital lobe (Fig. 2A). CT-guided percutaneous
needle biopsy of the pulmonary lesion proved adenocar-
cinoma. After refusing chemotherapy with toxic agents,
gefitinib (AstraZeneca, UK) was given at a daily dose of
250 mg as the first-line treatment for NSCLC combined
concurrently with whole brain irradiation (WBRT) for
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any medium, provided the original work is properly cited.Figure 1 Case 1. A: Prior to gefitinib therapy, chest CT scan shows a primary lesion (arrow) in the upper lobe of right lung and multiple
pulmonary metastatic nodules (arrowheads) in both lungs. B: One month later with gefitinib therapy, chest CT scan shows significant shrinkage
of the primary lesion (arrow) as well as marked absorption of metastatic nodules.
Figure 2 Case 1. A: Contrast-enhanced T1-weighted brain MRI shows multiple metastatic lesions, with the largest one (arrow) in the left
occipital lobe. B: One month later with gefitinib therapy together with two weeks’ WBRT, T1-weighted MRI demonstrates a subacute hematoma
(arrow) in the metastatic lesion.
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total dose of 30 Gy with a fraction size of 3 Gy over 2
weeks. During the course of treatment, mild skin rash
and nausea and vomiting developed but were well toler-
ated. One month later, chest CT showed significant
shrinkage of the primary lesion and marked absorption
of pulmonary metastases (Fig. 1B). Meanwhile, the
patient began to feel recurrent headache and nausea,
and brain MRI demonstrated a left occipital lobe mass
that was consistent with a subacute hematoma (Fig. 2B).
The platelet counts and prothrombin time and activated
partial thromboplastin time were within normal ranges.
The patient had no history of diabetes or hypertension
or coagulation disorders. During hospitalization the
patient had no history of trauma. Except for mild to
moderate headache and nausea, the patient complained
of no other discomfort such as impaired orientation to
person and place, hemidysesthesia or hemiopia.
The patient was discharged from hospital after one
week’s supportive treatment with mannitol and
methylprednisolone.
Case two
A 75-year-old male, an ex-smoker, was diagnosed with
right lower lobe lung cancer in July 2007, and under-
went operation after routine staging procedures. The
pathology was adenocarcinoma with positive margins
and ipsilateral hilar and mediastinal lymph node metas-
tasis (Stage pT3N2M0). Postoperative adjuvant
chemotherapy and thoracic radiotherapy (59 Gy/32 frac-
tions) were administered. The patient was well tolerant
to these therapies and without evidence of illness until
July 2008, when CT scans demonstrated diffuse pulmon-
ary metastatic dissemination (Fig. 3A) and a metastasis
in right hepatic lobe. The patient was given gefitinib at
a daily dose of 250 mg. CT scans about 2 months later
showed near-CR (Complete Response) of the pulmonary
lesions (Fig. 3B). After five months’ medication of gefiti-
nib, the patient developed severe bilateral paronychia.
This patient had an operation of nail arrachement in
November 2008. In March 2009, the patient developed
right limb numbness and unstable walking. Brain MRI
demonstrated a metastatic tumor in the left thalamus
with intratumoral hemorrhage (Fig. 4). The platelet
counting of the patient was 143,000/mm
3 and there
were no other underlying disorders that might be
related to the brain hemorrhage. WBRT was recom-
mended but the patient preferred watchful waiting. On
5th June 2009, more metastatic lesions with evidence of
bleeding were found on brain MRI and subsequently
WBRT (30 Gy/15 fractions) was administered to the
patient. The patient is now still alive with mild right
hemiparesis.
Discussion
Epidermal growth factor receptor (EGFR) is a member
of the HER tyrosine kinase growth factor receptor family
that signals cellular differentiation, proliferation,
Figure 3 Case 2. A: Chest CT scans shows pulmonary metastatic dissemination (arrows) from a previously operated NSCLC in the right lung. A
patchy shadow (arrowhead) representing radiation-induced fibrosis is also observed. B: About 2 month later with gefitinib therapy, chest CT
scan shows significant absorption of the metastatic lesions.
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variety of human cancers including NSCLC (40%-80%),
colorectal (25%-77%), pancreatic (30%-50%), breast
(15%-30%), ovarian (35%-70%), prostate (40%) and gas-
tric (33%) cancers [1]. Among the above-mentioned can-
cers, NSCLC was one of the most frequently studied
objects of EGFR-targeted therapy, as evidenced by such
clinical trials as INTEREST, ISEL (for gefitinib), and
BR21 and SATURN (for erlotinib, another EGFR-TKI)
[2,4,10,11].
Gefitinib (ZD1839, Iressa), a selective inhibitor of
EGFR tyrosine kinase (EGFR-TKI) which is competitive
with the combination of EGFR tyrosine kinase, acts
through blocking the signal transduction pathway of
epithelial growth factor and thereby inhibiting the prolif-
eration and metastasis, and, promoting the apoptosis of
tumor cells [1]. The orally administered gefitinib has
achieved a great effect since its approval by FDA in
2003, for it has less toxicity compared with traditional
cytotoxic chemotherapy. In addition to an extremely
small number of fatal interstitial pneumonia reported
[12], the common adverse drug reactions of gefitinib are
diarrhea, skin rash, dry skin, nausea and vomiting.
On most occasions these reactions are mild and reversi-
ble. Other less common adverse effects include pruritus,
anorexia, asthenia, and weight loss [13]. For the above
reasons, gefitinib has been used as the second or third
line therapy for advanced and metastatic NSCLC, or
even evaluated as the first line therapy (IPASS trial) for
a subset of patients with NSCLC [14]. Our first case was
administered gefitinib without prior cytotoxic therapies.
Targeted therapies also aim at other signal transduc-
tion pathways like vascular endothelium growth factor
(VEGF). It was reported that anti-angiogenic therapy
(AAT) had led to serious hemorrhagic events in
NSCLC, particularly in those of squamous cell origin
[15]. An early phase I trial of bevacizumab, an anti-
VEGF monoclonal antibody, also detected a case of
intracranial hemorrhage from a choriocarcinoma brain
metastasis. However, a recent phase II trial, AVF3752g,
showed safety of bevacizumab in patients with NSCLC
and previously treated brain metastases [16]. On the
other hand, anti-EGFR therapy has seldom been warned
against increased risks of bleeding, except a few case
reports of anecdotal experience.
There has been a case report in which severe alveolar
hemorrhage occurred after four weeks’ gefitinib therapy
in a 56-year-old man of NSCLC in Japan [9]. Recently,
another two reports on bilateral subdural hemorrhage
(SDH) after oral gefitinib administration have been pub-
lished [7,8]. In one, a 75-year-old woman was diagnosed
as stage IV NSCLC and was introduced to take gefitinib
at a daily dose of 250 mg. About 7 months later, the
patient gradually developed headache and weakness, and
CT demonstrated bilateral SDH another 2 months later.
Although there was no obvious evidence of CNS
Figure 4 Case 2. A: T1-weighted brain MRI shows a metastatic lesion of heterogeneous signal intensities in the left thalamus (arrow).
Components of hyper-signal intensities represent subacute hemorrhage. B: This lesion is also of heterogeneous signal intensities on T2-weighted
images, with components of hypointense hemosiderins representing chronic hemorrhage (arrow). C: Contrast-enhanced MRI shows
inhomogeneous enhancement of the lesion (arrow).
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might had resulted from obstruction of dural vessels by
latent dural metastasis and was also suggested as a pos-
sible adverse event of gefitinib therapy. Notably, the
above-described two cases developed hemorrhagic
events without CNS metastasis. Huang et al [8] reported
another case where a 57-year-old male developed bilat-
eral SDH after WBRT combined with EGFR-TKIs for
NSCLC with brain metastases. Gefitinib was replaced
with erlotinib on the 5th day after WBRT. During a
follow-up period with erlotinib alone after completing
WBRT, the patient developed bilateral SDH. The
authors did not make a clear explanation for the com-
plication. Apart from the above reports of hemorrhagic
events that might be related to gefitinib in NSCLC,
there was also a recent phase III study showing gefitinib
dose-dependently increased tumor hemorrhage-type
events in recurrent squamous cell carcinoma of the
head and neck [17].
In the current report, two patients developed brain
metastasis hemorrhage after taking gefitinib. Though in
our first case brain tumor hemorrhage developed one
month after a combination of gefitinib and WBRT, it is
still possible that gefitinib played a role. There were no
comorbiditis such as thrombocytopenia, coagulation
abnormalities or other underlying cerebrovascular dis-
eases or head trauma, and our own experience and
reports from other authors suggested that WBRT alone
was unlikely to be the cause of tumoral hemorrhage of
brain metastases, but rather could decrease the hemor-
rhagic events through blunting angiogenesis and nor-
malizing tumor vasculature [18,19]. As considerable
studies have demonstrated gefitinib to be a radiation
sensitizer in the treatment of a variety of tumors includ-
ing NSCLC, head and neck, breast, and colorectal can-
cers [20,21], we think EGFR-targeted therapy may have
strengthened the role of radiation-induced vascular
occlusion and subsequent post-ischemic hemorrhage.
Furthermore, gefitinib in combination with WBRT
might lead to rapid shrinkage of brain metastasis and
avascular necrosis, and induce reconstruction of micro-
vasculature and vascular abnormality, subsequently lead-
ing to tumoral bleeding. This is especially true for those
with high expression or mutations of EGFR. Unfortu-
nately, our two cases have not been performed that kind
of test, though patients now in our institute are strongly
encouraged to take such test before taking gefitinib or
other TKIs.
In the second case, hemorrhagic brain metastasis was
found 8 months after gefitinib monotherapy. Before
that, the patients also experienced severe paronychia
and underwent a nail arrachement three months after
gefitinib administration. MRI showed evidence of both
subacute (hyperintensities on T1-weighted image) and
chronic (hypointensities on T2-weighted image) compo-
nents of bleeding, with no obvious perilesional edema,
which might accounted for the mild symptoms and
signs of the patients. For the above reasons, the patient
was not immediately administered WBRT until some
new hemorrhagic metastases were detected in other
parts of the brain. As reported in the literature, the inci-
dence of spontaneous intracranial hemorrhage from
NSCLC with brain metastasis seemed to be very low
(about 1.2%), though higher than those without CNS
metastasis [22,23]. Furthermore, recent studies on EGFR
inhibition with gefitinib also showed its influence on
angiogenesis [24]. Hence, though whether the brain
metastasis hemorrhages were just coincidence or as a
result of gefitinib therapy remain to be further con-
firmed, it seems possible that gefitinib might be involved
in the brain hemorrhage in our two cases. Interestingly,
there is a study on treatment of brain metastasis from
NSCLC with WBRT and gefitinib which showed acute
side effects were generally well tolerated, and no hemor-
rhagic events were mentioned [6], our experience sug-
gest that caution should be taken when gefitinib is used
in combination with WBRT.
Conclusion
In summary, from our cases and others reported in the
literature, we speculate that brain metastasis hemor-
rhage could be a possible adverse drug reaction of gefiti-
nib for treatment of NSCLC. With increasing use of
gefitinib, especially in those patients with EGFR over-
expression or mutations, it is reasonable to suggest that
clinicians be highly cautious about this possible
complication.
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